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bstract
The central objective of the current study was to investigate the potential in vitro anti-proliferative properties of the par-
nt ligand, coumarin-dioxy-acetic acid (cdoaH2), and its copper complex, copper-coumarin-dioxyacetic acetate-phenathroline
[Cu(cdoa)(phen)2]) using four human-derived model cell lines, two neoplastic and two non-neoplastic. In addition, selected
echanistic studies were carried out using one of the neoplastic-derived model cell lines, Hep-G2. Results obtained show that
he complex, rather than the ligand, could alter the proliferation of both human neoplastic renal (A-498) and hepatic (Hep-G2)
ells. Furthermore, hepatic non-neoplastic cells (Chang) appeared to be less sensitive. However, this effect was not mirrored in non-
eoplastic renal (HK-2) cells, a profile shared with cisplatin. The observed anti-proliferative effect appeared to be concentration-
nd time-dependant, and could be attributed to the complex, rather than any of the component parts, i.e. 1,10-phenanthroline, the
oumarin ligand, or the simple metal salt. Furthermore, the complex was shown to decrease DNA synthesis, but did not intercalate
ith it. Based on IC50 values, [Cu(cdoa)(phen)2] was shown to be almost six times more potent than cisplatin. Moreover, there was
o evidence to show that P-glycoprotein (P-gp)-mediated multi-drug resistance (MDR) was likely to play a role in decreasing the
nti-proliferative activity of the complex. Cytological stains, analysis of genomic DNA, and biochemical assays [caspase-3 and -9
nd cleaved poly(ADP-ribose)-polymerase protein], suggested that cell death could switch between apoptosis and necrosis, and this
ffect appeared to be concentration-dependent. Additionally, flow cytometric analysis showed that the complex functioned through
n alteration in cell cycle progression. Taken together, [Cu(cdoa)(phen)2] has been shown to be a more potent anti-proliferative
gent than either the ligand or cisplatin, and is capable of altering key biochemical events leading to the execution of apoptotic
nd/or necrotic cell death, suggesting that it is worthy of further investigation.
2007 Elsevier Ireland Ltd. All rights reserved.
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1. IntroductionThere have been a number of reports highlighting the
use of transition metal complexes as anticancer agents
[1]. Probably the best known of these is cisplatin [cis-
diamminedichloroplatinum(II)] which has been widely
ed.
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used in the treatment of a variety of cancers, especially
testicular cancer, with a 70–90% cure rate. When com-
bined with other drugs, it has successfully been used to
treat brain, ovarian, bladder and breast cancer [2]. The
clinical success of cisplatin is limited by its significant
side effects, such as nausea, vomiting, severe nephro-
toxicity and genotoxicity [2]. The use of cisplatin and
related platinum complexes as anti-cancer agents has
stimulated a search for other active transition metal com-
plexes which are as, or more effective, but with lesser side
effects.
Coumarins comprise a very large class of com-
pounds found throughout the plant kingdom [3,4]. The
bio-activity of coumarin and more complex related
derivatives appears to be based on the coumarin
nucleus [5–7]. Biological effects observed include anti-
bacterial [8], anti-thrombotic and vasodilatory [9],
anti-mutagenic [10], lipoxygenase and cyclooxygenase
inhibition [11,12], and scavenging of reactive oxygen
species, as well as anti-tumourigenic [13–19]. Since the
late 1980s, a number of in vivo studies have investi-
gated the possible use of coumarins in the treatment of
malignant melanoma and renal cell carcinoma [20,21].
All of these studies have demonstrated a significant
response rate following coumarin treatment alone or in
combination therapy. The in vitro effects of coumarins
on the growth of malignant melanoma and renal cell
carcinoma-derived cell lines showed that coumarin
and 7-hydroxycoumarin, along with several of their
derivatives were potent cytotoxic and cytostatic agents
[15,17–19]. Recent studies carried out in our laboratory
compared the anti-proliferative capability of a series of
natural and synthetic nitro- and hydroxylated-derivatives
of coumarin, including 6-nitro-7-hydroxycoumarin and
7,8-dihydroxycoumarin, using both renal adenocarci-
noma and malignant melanoma-derived cell lines. These
compounds were shown to be potent cytotoxic agents,
capable of killing cancer cells by modulation of key
biochemical pathways such as mitogen-activated protein
kinases [17–19].
Interest in metal–coumarin complexes has arisen
from the search for novel lead compounds, along with
the desire to improve the pharmacological profile of
established anti-neoplastic agents. Kokotos et al. [22]
synthesised a number of amino-coumarin–platinum(II)
complexes and evaluated their in vitro anti-proliferative
activity using a colonic carcinoma cell line (Caco-
2). They screened a number of coumarins with an
amino group at position six or seven and methyl
groups at various positions around the coumarin
nucleus. These researchers found that the most potent
platinum–coumarin complex had functional groupsteractions 168 (2007) 143–158
attached at position six. More recently, Manalov et al.
[23] investigated the in vitro cytotoxicity of a number of
coumarin complexes with the rare earth metal, cerium,
using both Burkitt lymphoma (P3HR1) and leukemic
(THP-1) cell lines. These researchers found that com-
plexation resulted in a 40% increase in cytotoxicity, com-
pared to the metal-free ligand. Additionally, Manalov et
al. [23] studied the effects of coumarin complexed to zir-
conium. Here again it was found that metal–coumarin
complexes were more active than either the inorganic
metal ion or the coumarin ligand on their own.
1,10-Phenanthroline (phen) and substituted deriva-
tives, both in the metal-free state and as ligands
co-ordinated to transition metals, disturb the functioning
of a wide variety of biological systems [24]. Further-
more, when metal-free N,N′-chelating bases are found to
be bioactive it is usually assumed that the sequestering
of trace metals in situ is involved, and that the resulting
metal complexes are the active species [25,26]. Previous
work has shown that metal–phen complexes, namely
[Cu(phen)2(mal)]·2H2O, [Mn(phen)2(mal)]·2H2O
and [Ag2(phen)3(mal)]·2H2O (malH2 = malonic acid)
inhibit growth of the fungal pathogen Candida albi-
cans by around 95% in a concentration range of
1.25–5.0g/ml [27,28].
One of the most biologically active of the metal–phen
complexes has been shown to be [Cu(phen)2]2+. This
agent has been shown to promote hydroxyl radical for-
mation from molecular oxygen by redox-cycling and
could therefore be considered suitable for stimulating
the production of reactive oxygen species. Transition
metal cations such as Cu(II) and Fe(II) bind to neg-
atively charged DNA and have been shown to play
an important role in the local formation of •OH radi-
cals [29,30]. One of the consequences of high copper
levels in the body is an increase in the rate of radi-
cal formation leading to oxidative damage, which leads
to a disruption of lipid bilayers due to oxidation and
cleavage of vulnerable unsaturated fatty acid residues
of phospholipids [31]. Alterations in protein function
are also promoted through oxidation of thiol and possi-
bly amino groups. Gene expression may also be altered
due to oxidation of guanosine and adenosine residues
in nucleic acids, or altered transcription factor/growth
factor activities [31]. Tsang et al. [32] reported that
incubation of a human hepatic cell line (Hep-G2) with
[Cu(phen)2]2+ resulted in internucleosomal DNA frag-
mentation, a hallmark of apoptosis. Zhou et al. [33]
also reported G1-specific apoptosis in a liver carci-
noma cell line (Bel-7402), caused by [Cu(phen)2]2+.
Additionally, this complex was shown to up-regulate
DNA-binding activity of p53, a pivotal molecule in the
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Based on the above, and given the anti-cancer prop-
rties of metal-based derivatives of both coumarin and
hen, we decided to determine whether a complex com-
osed of each of these component parts, namely cdoaH2
nd its copper complex, copper-coumarin-dioxyacetic
cetate-phenathroline ([Cu(cdoa)(phen)2] (Fig. 1) could
ecrease the in vitro proliferative activity of human-
erived cancer cell lines. Therefore, the central objective
f this study was to use a number of in vitro-based
echniques to illustrate whether these agents could selec-
ively kill cancer cells, and in doing so elucidate their
olecular mechanism of action. In addition, comparative
tudies were carried out in order to highlight poten-u(cdoa)(phen)2] used in this study.
tial benefits, relative to one of the best known and
most widely used metal-based anti-cancer drugs, cis-
platin.
2. Materials and methods
2.1. Test compounds and reagents
Cisplatin, phen, Cu(ClO4)2 and dimethyl sulfox-
ide (DMSO) were purchased from Sigma–Aldrich,
Ireland Ltd. and used as received. The preparation
of the novel ligand cdoaH2 and its copper complex
([Cu(cdoa)(phen)2]) are described in full in another
publication [35]. Structure and purity analysis was con-
firmed by thin layer chromatography, infrared analysis,
ical In146 B. Thati et al. / Chemico-Biolog
1H and 13C NMR spectroscopy, along with elemental
analysis. The X-ray crystal structure of the copper(II)
complex showed that the copper complex had a trigo-
nal bipyramidal geometry about the metal centre, with
the copper atom bound to four nitrogen atoms of the
two chelating phen ligands and a single oxygen from
one of the carboxylate moieties of the cdoa2− lig-
ands.
The chemiluminescence substrate Luminol, was
purchased from Pierce Laboratories (UK), while the anti-
body specific to cleaved poly(ADP-ribose)polymerase
(PARP) was purchased from New England Biolabs,
and the DNA fragmentation kit was purchased from
Calbiochem, UK. Jsb-1, the antibody specific for
P-glycoprotein (P-gp) was purchased from Cappell,
UK. All cell culture reagents and culture media
were purchased from Euroclone, UK, unless otherwise
stated.
2.2. Model cell lines
A-498 (human kidney adenocarcinoma), HK-2
(human proximal tubular), Chang (human hepatic) and
Hep-G2 (human hepatocellular carcinoma) cells were
purchased from the American Type Culture Collec-
tion, Manassas, USA. A-498, Chang and Hep-G2 cells
were maintained in Eagles Minimum Essential Medium
(EMEM) with Earle’s Balanced Salt Solution, con-
taining 1.5 g/L sodium bicarbonate, 2 mM l-glutamine,
0.1 mM non-essential amino acids, 1 mM sodium pyru-
vate, 100 U/ml penicillin, 100g/ml streptomycin and
10% (v/v) foetal bovine serum (FBS) (Sigma). HK-2
cells were maintained in Dulbecco’s Modified Eagles
Medium/Nutrient Hams F12 (50:50, v/v), supplemented
with 2 mM l-glutamine, ITS (5g/ml bovine insulin,
5g/ml human transferrin, 5 ng/ml selenium), 36 ng/ml
hydrocortisone, 4 pg/ml 3,3′,5-tri-iodo-l-thyronine, and
10 ng/ml epidermal growth factor. All cell lines were
grown at 37 ◦C in a humidified atmosphere with 5% CO2,
and were in the exponential phase of growth at the time
of inclusion in assays.
Chinese hamster ovary cells (CHO-K1 and CHRC5)
were kindly provided by Dr. V. Ling, Ontario, Canada.
CHO-K1 cells were maintained in Nutrient Hams
F12, containing 2 mM l-glutamine, 100 U/ml peni-
cillin, 100g/ml streptomycin and 10% (v/v) FBS.
CHRC5 cells were maintained in EMEM, Alpha modifi-
cation (without ribonucleosides and deoxynucleosides),
containing 2 mM l-glutamine, 100 U/ml penicillin,
100g/ml streptomycin and 10% (v/v) FBS. All cell
lines were grown at 37 ◦C in a humidified atmosphere
and in the presence of 5% CO2.teractions 168 (2007) 143–158
2.3. Assessment of cytotoxicity using MTT assay
cdoaH2, [Cu(cdoa)(phen)2], phen, cisplatin and
Cu(ClO4)2 were dissolved in DMSO, diluted in cul-
ture media and used to treat model cells over a range
of drug concentrations for periods of 4, 24 and 96 h.
The maximum percentage of DMSO present in any
well was 0.05% (v/v). Cells were seeded in sterile
96 well flat-bottomed plates (Sarstedt) at a density of
5 × 104 cells/ml and grown in 5% CO2 at 37 ◦C. A minia-
turised viability assay using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) was
carried out according to the method described by
Mosmann [36]. In metabolically active cells, MTT is
reduced by the mitochondrial enzyme succinate dehy-
drogenase to form insoluble purple formazan crystals
that are subsequently solubilised, and the optical den-
sity (OD) measured spectrophotometrically. Therefore,
drug-treated cells were assayed by the addition of 20l
of 5 mg/ml MTT in 0.1 M phosphate buffer saline (PBS),
pH 7.4. Following incubation for 4 h at 37 ◦C, the over-
lying medium was aspirated with a syringe and 100l
of DMSO was added to dissolve the formazan crystals.
Plates were agitated at high speed to ensure complete
dissolution of crystals and OD was measured at 550 nm
using an Anthos HT-II microtitreplate reader. Viability
was expressed as a percentage of solvent-treated con-
trol cells. This assay had five replicates per assay, and
each experiment was carried out on at least three sepa-
rate occasions. The IC50 was calculated and defined as
the drug concentration (M) causing a 50% reduction in
cellular viability.
2.4. Confirmation of MDR-1 phenotype
The pleotrophic drug-resistant cell line CHRC5, has
previously been shown to over-express the MDR-1
gene product, P-gp-170 and exhibit cross-resistance to
structurally dissimilar drugs, while the P-gp-negative
CHO-K1 cell lines fails to exhibit the MDR-1 phenotype
[37]. To confirm these drug phenotypes, both CHRC5
and CHO-K1 cells were assessed for chemosensitivity
by exposure to a known anti-cancer drug, vinblastin. The
viability of CHRC5 and CHO-K1 cell lines was assessed
in parallel using a 96-well format with increasing con-
centration of vinblastin. Briefly, the cell density of both
cell lines was adjusted to 5 × 104 cells/ml, and 100l of
cell suspension was added per well to a 96-well plate
(Falcon). Following overnight incubation, a concen-
trated stock solution of each test compound was prepared
in DMSO was stored at −20 ◦C, thawed directly prior to
the assay, and the required dilutions were prepared by
ical Int
s
m
0
o
u
t
o
2
d
[
p
[
p
w
w
o
o
2
E
i
u
p
t
m
1
1
a
L
3
P
g
a
(
a
i
2
f
a
d
(
1
w
bB. Thati et al. / Chemico-Biolog
erial dilution in complete culture medium. The maxi-
um concentration of DMSO present in all wells was
.05% (v/v), a concentration which exhibited no effect
n cell morphology or growth. Viability was determined
sing the MTT assay [36]. The relative degree of resis-
ance for each cell line was determined by comparison
f the IC50 values [38].
.5. DNA synthesis studies
DNA synthesis was determined using 5-bromo-2-
eoxyuridine (BrdU) colourimetric incorporation assay
39]. A-498 and Hep-G2 cells were seeded into 96 well
lates and allowed to adhere overnight. cdoaH2 and
Cu(cdoa)(phen)2] was added and incubated for 96 h
rior to the addition of BrdU (10M per well). Plates
ere then incubated at 37 ◦C for 4 h and incorporation
as quantified using ELISA (Roche). The significance
f any reduction in DNA synthesis was determined using
ne-way ANOVA.
.6. DNA binding studies
pGEM-3Z plasmid DNA was purified from
scherichia coli [strain JM 109 and previously cultured
n LB broth (Oxoid), containing 50g/ml ampicillin]
sing a Qiagen isolation kit (Qiagen Ltd.). DNA
urity and concentration was determined spectropho-
ometrically using A260/A280 spectrophotometric
easurements. DNA concentration was adjusted to
g/ml using 10 mM Tris–HCl, pH 7.5, containing
mM EDTA. Drug binding assays were carried out
ccording to the method described by Lorcozio and
ong [40]. Briefly, DNA was incubated for 2 h at
7 ◦C, with doxorubicin employed as a positive control.
lasmid DNA was separated on a 1% (w/v) agarose
el in TBE (80 mM Tris–HCl, pH 8; 40 mM boric acid
nd 2 mM EDTA), and stained with ethidium bromide
5g/ml in TBE). Bands were visualised by irradiation
t 300 nm and photographed using a Pharmaciae 3D
maging system.
.7. Morphological analysis
Preparations of Hep-G2 cells exposed to the complex
or either 4 or 24 h and then stained with methylene blue
nd eosin [41]. Drug-treated cells were grown in Petri-
ishes, washed once with PBS, once with PBS:methanol
1:1, v/v) and then fixed in 100% (v/v) methanol for
0 min. Following fixation, cell monolayers were rinsed
ith anhydrous methanol and stained with methylene
lue and eosin for 2 min. Monolayers were then agitatederactions 168 (2007) 143–158 147
for a further 2 min, destained by rinsing under a gen-
tle stream of water and then finally rinsed with distilled
water. Phase contrast microscopy was carried out using
a Ceti Phase Contrast Microscope.
Cells were also stained using a dye specific
for the detection of apoptotic cells, namely 4,6-
diamidino-2-phenylindole (DAPI). Briefly, a monolayer
of drug-treated cells was washed in PBS and fixed with
4% (w/v) paraformaldehyde for 30 min at room temper-
ature. These cells were then permeabilized with 0.2%
(v/v) Triton X in PBS and incubated with 1g/ml of
DAPI for 30 min. Cells were washed three times with
PBS and viewed using a fluorescent microscope with
340/380 nm excitation filter at 60×magnification. Apop-
totic cells were confirmed by identification of intensely
stained, fragmented nuclei and condensed chromatin.
2.8. DNA fragmentation
Chromosomal DNA from drug-treated cells was
extracted using the Suicide-trackTM DNA ladder iso-
lation kit (Oncogene). Briefly, cells were cultured in
150 mm Petri-dishes and treated with complex at con-
centrations of 0, 7.5, 15 and 30M 24 h. Floating cells
were collected by centrifuging, while adherent cells were
harvested by scraping and then combined with collected
floating cells. All cells were then centrifuged together
and the resulting pellet, consisting of approximately
5 × 106 cells, was resuspended in 55l of lysis solution,
followed by the addition of 20l of RNase A solution
and incubated at 37 ◦C in a water bath for 1 h. Twenty-
five microlitres of DNA isolation solution was added and
tubes were incubated overnight at 50 ◦C. Five hundred
microlitres of re-suspension buffer (10 mM Tris–HCl,
pH 7.5, containing 1 mM EDTA) was then added to each
sample. Intact and fragmented DNA was precipitated
by the addition of 2l of Pellet-paintTM co-precipitant
followed by 60l of 3 M sodium acetate, pH 5.2 and
662l of 2-propanol. Samples were mixed by inversion
and then washed once in 70% (v/v) ethanol and once
in 100% (v/v) ethanol. Finally, DNA samples were air-
dried and resuspended in 50l of resuspension buffer
(10 mM Tris–HCl, pH 6.8) before analysis on 1.8%
agarose gels. Positive controls consisted of 1 × 106 HL-
60 cells (Human leukaemia cells) treated with 0.5g/ml
Actinomycin D for 24 h, both supplied by Oncogene.
2.9. Caspase activity assayActivation of ICE-family proteases/caspases initiates
apoptosis in mammalian cells [42]. Hep-G2 cells were
incubated with complex at concentrations of 0, 7.5, 15
ical In148 B. Thati et al. / Chemico-Biolog
and 30M for 24 h. Both floating and attached cells
were collected by centrifugation. Cells at a density of
1.5 × 106 cells/ml, were counted, washed with PBS and
then re-suspended in chilled cell lysis buffer (supplied in
the Caspase-3 colourimetric assay kit, Biovision, UK).
Cells were incubated on ice for 10 min and then cen-
trifuged for 1 min at 10,000 × g. The cytosolic fraction
(supernatant) was collected into a fresh tube and 50l
(2 mg/ml) of each protein sample was diluted with lysis
buffer and added to 50l of ×2 reaction buffer con-
taining, 10 mM DTT in a 96-well plate. Five microlitres
of 4 mM DEVD-pNA substrate (200M) was added to
each well and incubated at 37 ◦C for 1–2 h. OD was deter-
mined at 400 nm using an Anthos HT-II microtitreplate
reader. The fold increase in caspase-3 and -9 activities
was determined by comparing results to that obtained
with un-induced control.
2.10. Immunoblot analysis for PARP cleavage
Test agent was dissolved in DMSO, diluted in cul-
ture media and used to treat model cells growing in
100 mm Petri-dishes. Cells were exposed to complex
for 24 h at concentrations of 0, 15 or 30M. Both
floating and attached cells were washed twice with ice-
cold 0.1 M PBS, pH 7.4, harvested by scraping and
centrifuged at 8000 × g for 5 min. Whole cell extracts
were prepared by re-suspension in lysis buffer [M-per
lysing solution (Pierce, UK)], supplemented to contain
1 mM EDTA, 1 mM EGTA, 1 mM sodium vanadate,
1 mM phenylmethylsulfonylflouride (PMSF), 2g/ml
leupeptin and 2g/ml aprotinin. After 15 min on ice,
the mixture was clarified by centrifugation for 5 min at
10,000 × g and the resultant supernatant collected. Forty
micrograms of total protein lysates were resolved using
electrophoresis on a 12% polyacrylamide gel (PAGE)
and transferred to nitrocellulose membranes. The level
of protein expression was determined using specific
primary antibodies, followed by peroxidase-conjugated
secondary antibodies, visualisation was achieved using
a chemiluminescent substrate (Luminol) and exposure
to X-ray film.
2.11. Cell cycle analysis
Hep-G2 cells were grown in 100 mm Petri-dishes and
exposed to either solvent or complex at concentrations
of 0, 4, 8 or 16M for 24 h. Both floating and attached
cells were collected by centrifugation, washed twice in
ice-cold PBS, pH 7.4, harvested by trypsinisation and
collected by centrifugation. The effect of treatment with
the complex on cell cycle was determined using flowteractions 168 (2007) 143–158
cytometric analysis according to the method of Nunez
[43]. Briefly, cell suspensions were fixed and perme-
abilised by vigorous addition of nine volumes of ice-cold
70% (v/v) ethanol and stored at −20 ◦C for a mini-
mum of 24 h, prior to analysis. Cells at a density of
approximately 1 × 106 were re-suspended in 800l of
propidium iodide staining solution (20g/ml propidium
iodide and 200g/ml RNase A in PBS, pH 7.4) and
incubated in the dark at room temperature for 30 min.
The percentage of cells in sub-G1, G0/G1, S and G2/M
phases of cell cycle was determined and analysed from at
least three independent experiments using Cell QuestTM
software (Becton Dickinson).
2.12. Statistical analysis
Statistical analyses were performed using the statisti-
cal software package Mini-tab®. Statistical evaluation of
the untreated control cells along with drug- and solvent-
treated cells was calculated using one-way ANOVA
(analysis of variance). A probability of 0.05 or less
was deemed statistically significant. The following nota-
tion was used throughout; *P < 0.05, **P < 0.01 and
***P < 0.001, relative to control.
3. Results
cdoaH2 and [Cu(cdoa)(phen)2] shown in Fig. 1, along
with phen, cisplatin and Cu(ClO4)2 were initially incu-
bated with four human-derived cell lines, two carcinoma
(A-498 and Hep-G2) and two non-carcinoma (Chang
and HK-2), and their cytotoxicity was determined using
MTT (Figs. 2 and 3). Data obtained for both the ligand
and the complex following 4, 24 and 96 h continu-
ous incubation, was used to calculate IC50 values and
are shown in Figs. 2–4, along with Table 1. All com-
pounds displayed a concentration- and time-dependent
anti-proliferative profile, and in all four cell lines, with
the two neoplastic-derived cell lines, Hep-G2 and A-498,
appearing to be most sensitive (Fig. 3). Also, based on
IC50 values it would appear that the complex was statis-
tically more active than either the parent ligand or phen.
Also, in order to establish that the anti-proliferative effect
observed was due to the complex rather than the simple
salt, it was decided to include Cu(ClO4)2 in the test proto-
col. Data presented in Table 1 suggests that Cu(ClO4)2 is
not capable of displaying anti-profilerative effects blow
250M in any of the four model cell lines used here. In
addition, we investigated the possibility that these agents
could act as a potent anti-proliferative agent in neoplastic
(Hep-G2 and A-498) rather than non-neoplastic-derived
(Chang and HK-2) cell lines (Fig. 3). The results pre-
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Table 1
Anti-proliferative activity of test agents was determined using Hep-G2, Chang, A-498 and HK-2 cells, following 96 h continuous incubation and
MTT assay
Compound Hep-G2 (IC50
(M) ± S.E.M.)
CHANG (IC50
(M) ± S.E.M.)
A-498 (IC50
(M) ± S.E.M.)
HK-2 (IC50
(M) ± S.E.M.)
[cdoaH2] >250 >250 >250 >250
[Cu(cdoa)(phen)2]·8.8H2O 2.5 ± 1.4* 14 ± 2.2* 2.5 ± 0.9* 3 ± 1.1*
Cu(ClO4)2 >250 >250 >250 >250
Phen 4.5 ± 0.9 7 ± 1.2 5.5 ± 1.2 9 ± 1.5
C 45 ± 2.
A 50 valu
.05.
s
c
t
H
c
i
n
t
f
s
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p
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t
f
oisplatin 15.0 ± 2.65
graph of viability vs. drug concentration was used to calculate all IC
* Value is statistically distinct from that of the parent ligand at P < 0
ented in Fig. 3 and Table 1 would suggest that Hep-G2
ells were significantly more sensitive than Chang, but
his effect was not reflected in the non-neoplastic renal
K-2 cells. Thus, there is insufficient evidence to con-
lude that the complex can act in a cyto-selective manner
.e. sparing non-neoplastic cells. However, it is worth
oting that the complex displayed a similar profile to
hat seen with cisplatin. Furthermore, the IC50 values
or the complex using A-498 and Hep-G2 cells, were
hown to be between 5.6 and 6 times greater, respec-
ig. 2. Dose–response curve for [cdoaH2], [Cu(cdoa)(phen)2] and
hen using (A) Hep-G2 and (B) A-498 cells, following 96 h incubation,
s assessed by MTT assay. In both cell lines, the complex produced
he greatest concentration-dependent decrease in cellular proliferation,
ollowing 96 h incubation. Results are expressed as percentage viability
f solvent-treated control cells. Bars indicate ± S.E.M., n = 3.9 14.0 ± 2.3 18 ± 2.7
es (M), n = 5.
tively, than those seen with ciaplatin. Taken together, the
data presented would suggest that the complex was sig-
nificantly more anti-proliferative than cisplatin, with a
similar profile existing across all four model cell lines.
In order to provide information on the anti-
proliferative effect of the complex following relatively
short exposure times, MTT-based viability assays were
carried out at both 4 and 24 h. The IC50 values calculated
were shown to be 49 and 15M, respectively for the
most sensitive cell line, Hep-G2 (Fig. 4). Consequently,
Fig. 3. Dose–response curve for (A) [cdoaH2] and (B)
[Cu(cdoa)(phen)2] using Hep-G2, Chang, A-498 and HK-2
cells following 96 h incubation, as assessed by MTT assay. In both
cases, the complex produced the greatest concentration-dependent
decrease in cellular proliferation. Results are expressed as percentage
viability of solvent-treated control cells. Bars indicate ± S.E.M., n = 3.
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Table 2
Anti-proliferative activity and resistance factor used to confirm multi-drug resistance phenotype and demonstrating whether [Cu(cdoa)(phen)2] was
a substrate for P-gp
Test agent CHO-K1 CHRC5
IC50 ((M) ± S.E.M. IC50 ((M) ± S.E.M. Resistance factor
[Cu(cdoa)(phen)2] 3.56 ± 0.47 6.83 ± 0.61 1.9
Vinblastine 0.013 ± 0.005 0.48 ± 0.04 37
HRC5
resistance factor of 37. This value is consistent with a pre-
viously published value of 40 [18]. In contrast, the data
obtained for the complex illustrated a substantially lower
resistance factor, suggesting that it is not a potentialThe resistance factor was calculated by division of the IC50 for the C
representative of three independent experiments.
these concentrations and time points were included in
subsequent mechanistic assays, unless otherwise stated.
It has been established that over-expression of P-gp
is responsible for the “classical” type of MDR. This
has been defined as the simultaneous resistance of a
cell against a variety of structurally dissimilar cytotoxic
drugs [44,45]. Using a cellular model of MDR-1, we con-
firmed the MDR phenotype by immunological detection
of P-gp along with chemosensitivity testing using vin-
blastine. This method allows the MDR phenotype to be
assessed by detection of the protein effector molecule
and by comparison of the relative toxicities (IC50) in the
MDR-positive and -negative cell lines. Consequently,
drugs that display less or equal effects in the MDR-
positive cell line could be potential MDR substrates. Fur-
thermore, comparison of the relative experimental toxic-
ities allows calculation of a resistance factor. This factor
was calculated by dividing the drug toxicity (IC50 value)
observed in the MDR-positive cells by the drug toxic-
ity in the MDR-negative cells. In addition, the integrity
of the two model cells lines was confirmed by Western
Fig. 4. Dose–response curves for [Cu(cdoa)(phen)2] using Hep-G2
cells following 4 and 24 h incubation, as assessed by MTT assay. This
complex caused a concentration- and time-dependent decrease in cel-
lular proliferation. Results are expressed as percentage viability of
solvent-treated control cells. Bars indicate ± S.E.M., n = 3.cell line by the IC50 for the CHO-K1 cell line. Results presented are
Blot Analysis. P-gp-170 was not detected in the MDR
negative cells (CHOK1), while there was considerable P-
gp expression in MDR positive cells (CHRC5) (data not
shown). In addition, the results presented in Table 2 show
the cytotoxicity observed with vinblastine and the com-
plex and indicate that the MDR phenotype of the CHRC5
cells was retained, with vinblastine demonstrating aFig. 5. The effects of cdoaH2 and [Cu(cdoa)(phen)2] on DNA synthe-
sis in both (A) A-498 and (B) on Hep-G2 cells was determined using
BrdU assays. Both compounds produced a concentration-dependent
decrease in DNA synthesis, and in both cell lines. Results are expressed
as percentage viability of solvent-treated control cells. Bars indi-
cate ± S.E.M., n = 3.
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Fig. 6. Electrophoretic mobility shift assays were used to determine
the effects of [Cu(cdoa)(phen)2] on the migration of pGEM-3Z super-
coiled plasmid DNA for 2 h at 37 ◦C. Results indicate that the complex
did not inhibit the migration of super-coiled (SC), linear (L) or open
circular (OC) forms of plasmid DNA, suggesting that it did not inter-
calate DNA. Lane 1 pGEM-3Z DNA (negative control); lane 2 positive
control (pGEM-3Z DNA and doxorubicin, 10M); lanes 3-5 pGEM-
3Z DNA and complex (1, 10, and 200M). Results presented are
representative of three independent experiments.
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DR-1 substrate. In addition, greater cytotoxicity was
bserved in the MDR-positive cell line, rather than the
DR-negative cell line (Table 2). In an attempt to elu-
idate the events responsible for the observed reduction
n cellular proliferation, the effect of both the complex
nd the ligand on DNA synthesis in both Hep-G2 and
-498 cells was determined using BrdU incorporation
ssays. Results obtained suggest that following a 96 h
he complex rather than ligand, caused a concentration-
ependent decrease in DNA synthesis (Fig. 5).
In order to explore the relationship between the
bserved anti-proliferative response and the possibility
hat DNA was a molecular target, intercalation stud-
es were carried out using electrophoretic mobility shift
ssays. Treatment of pGEM-3Z plasmid DNA with com-
lex at concentrations of 1, 10 and 200M did not
lter the migration of any of the three forms of DNA
super-coiled, linear and open-circular), unlike the pos-
tive control doxorubicin (Fig. 6). This indicates that
Cu(cdoa)(phen)2] does not function through DNA inter-
alation.
ig. 7. The effect of [Cu(cdoa)(phen)2] on the cellular morphology of Hep-G2
, 7.5, 15 and 30M (panels A–D, respectively), and assessed by methylene b
t 4 h and a concentration of 30M (panel D), there was a thinning of the
nd vacuolation of the cytoplasm (15 and 30M, panels C and D) cells bec
n contrast, treatment of cells with vehicle alone (panel A) appeared to have
ssociated with Hep-G2 cells.cells was assessed following 4 and 24 h incubation at concentrations of
lue and eosin, using phase contrast microscopy (60× magnification).
monolayer. Additionally, by 24 h, there was nuclear disintegration
ome rounded with progressive nuclear shrinkage and disintegration.
no visible effect, as cells retained the typical epithelial morphology
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Fig. 8. The effect of [Cu(cdoa)(phen)2] on the cellular morphology of Hep-G2 cells was assessed following 4 and 24 h incubation at concentrations
API st
nels B–
controlof 0, 7.5, 15 and 30M (panels A–D, respectively), and assessed by D
cells exposed to 7.5, 15 and 30M resulted in nuclear shrinkage (pa
became intensively stained and fragmented (panels B–D). In contrast,
The cytological effects of treatment with the com-
plex at concentrations of 0, 7.5, 15 and 30M for either
4 or 24 h were determined using methylene blue and
eosin (Fig. 7), along with DAPI staining (Fig. 8). The
results presented in Fig. 7 clearly suggest that the com-
plex as early as 4 h and a concentration of 30M (panel
D) resulted in a visible thinning of the monolayer, with
nuclear disintegration and vacuolation of the cytoplasm.
Furthermore, following 24 h and again at concentrations
of 15 and 30M, cells become rounded with progressive
nuclear shrinkage and disintegration, along with eventual
detachment from the culture dish. These changes are gen-
erally considered to be characteristic of the induction of
apoptotic and necrotic cell death. In contrast, treatment
of cells with vehicle alone (Fig. 7A) appeared to have
no visible effect, as cells retained the typical epithelial
morphology associated with Hep-G2 cells.
The effect of the complex on DNA integrity was
determined using DAPI. This stain is commonly used
to visualise nuclear morphology and detect the presence
of DNA condensation. Results presented in Fig. 8 show
that following 4 h, cells exposed to 7.5, 15 and 30M
caused nuclear shrinkage (panels B–D, respectively).
Furthermore, by 24 h, and at each of the test concentra-aining, using phase contrast microscopy (60× magnification). At 4 h,
D, respectively), while by 24 h, each concentration caused nuclei to
cells (panel A) exposed to vehicle alone displayed no visible effects.
tions, nuclei became intensively stained and the nuclear
material fragmented (panels B–D). Taken together, these
results may suggest the presence of both apoptotic and
necrotic cell death.
Analysis of DNA from apoptotic cells by agarose
electrophoresis is known to produce a characteristic
DNA ladder that is widely regarded as a biochemical
hallmark of apoptosis. Therefore, in order to confirm the
results observed in both Figs. 7 and 8, genomic DNA
was extracted from cells treated with complex and anal-
ysed. Consequently, both floating and attached cells were
collected for analysis. The results presented in Fig. 9
illustrate that the complex was capable of fragmenting
DNA. However, the exact nature of the fragmentation
patter was unclear, as increasing concentration of com-
plex caused band smearing. Thus, based on this result
alone, there remains the possibility that the complex may
cause both necrotic and apoptotic cell death.
Given the results obtained above, our next aim was
to examine the involvement of two specific caspases,
namely; caspases-3 and -9, which are known to play
a major role in the execution of apoptotic cell death.
Caspase-3 is known to be one of the main execu-
tioner/effector caspases which is activated by caspase-9
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Fig. 9. Internucleosomal DNA cleavage of Hep-G2 cells treated with
[Cu(cdoa)(phen)2] was determined following incubation (lanes 3–5
at concentrations of 7.5, 15 and 30M) for 24 h. Both floating and
attached cells were collected and analysed. Lane 1 consists of the
positive control provided in the kit consisted of 1 × 106 HL-60 cells
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Fig. 10. The effects of [Cu(cdoa)(phen)2] on caspase-3 and -9 activ-
ities were determined in Hep-G2 cells following 24 h incubation at
concentrations of 0, 7.5, 15 and 30M. The fold-increase in caspases-
3 and -9 activities was determined by comparison with that of the
solvent control. Data obtained suggests that caspase-3 activity was
significantly increased following incubation with concentrations of 15
and 30M, while caspase-9 was increased only at 30M. Results
ring in response to drug-treatment. Therefore, it was
decided to investigate the effect of the complex on cell
cycle events and examine the resultant histograms for
Fig. 11. The effect of [Cu(cdoa)(phen)2] at concentrations of 15
and 30M (panel A, lanes 1 and 2) on the proteolytic cleavage
of poly(ADP-ribose)polymerase (PARP) was determined in Hep-G2
cells, following 24 h incubation. Both floating and attached cells
were collected and analysed. A band corresponding to cleaved PARPHuman leukaemia cells) treated with 0.5g/ml Actinomycin D for
4 h. Lane 2 consists of the negative control consisting of vehicle alone.
esults presented are representative of three independent experiments.
42]. The results presented in Fig. 10 shows the fold-
ncrease in both caspase-3 and -9 activities following
4 h incubation with [Cu(cdoa)(phen)2]. The results
btained suggest that the activity of caspase-3 was
ignificantly increased following incubation with con-
entrations of 15 and 30M, while caspase-9 was
ncreased only at 30M. Furthermore, the complex
ppeared to produce a greater response in caspase-3,
elative to caspase-9 activity.
The results presented in Fig. 10 would suggest
hat cleavage of poly(ADP-ribose)-polymerase protein
PARP), is likely to occur as a consequence of caspase-
activation. This theory was subsequently confirmed
sing Western Blot Analysis (Fig. 11), where the com-
lex at test concentrations of 30M, was shown to cause
n increase in the amount of cleaved PARP. However,
his increase was not seen at the lower concentration of
5M. Taken together with the results from the caspase
ssays, it would indicate the complex at a concentration
f 30M, may cause induction of apoptotic cell death,
hrough activation of caspases-3 and -9, with subsequent
leavage of PARP.
The results presented in Fig. 5 showed that the com-
lex could bring about a significant and concentration-presented are representative of three independent experiments. Bars
indicate ± S.E.M. The asterisks indicate statistically significant differ-
ences to control: *P < 0.05 and **P < 0.01.
dependent decrease in DNA synthesis, suggesting that
DNA synthesis appeared to be a significant event occur-(85 kDa) was detected following drug-treatment at a concentration of
30M (panel A, lane 1). The same lysates were probed for the pres-
ence of -actin (45 kDa) as a normalisation control (panel B). Western
Blots presented are representative of three independent experiments.
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16M
n phase
rimentFig. 12. The effect of [Cu(cdoa)(phen)2] at concentrations of 4, 8 and
24 h incubation. Results show a concentration-dependent disruption i
A). Histograms presented are representative of three independent expe
evidence of apoptotic cell death. Hep-G2 cells were
exposed to test agent (4, 8, and 16M) for 24 h and
the percentage of cells entering each phase of the cell
cycle was determined. The results presented in Fig. 12B
show a concentration-dependent decrease in the % of
cells entering G0/G1 and G2/M. In addition, the % of
cells in S phase increased at the lower drug concentra-
tion (4M) and subsequently decreased at the highest
concentration studied (8 and 16M). Examination of
the resultant histograms (Fig. 12A) show that concentra-
tions of 8 and 16M lead to a dramatic increase in the
sub-G1 peak from 3.6% to 55.5%, respectively. Further-
more, a sub-G1 peak is widely regarded as representing
hypo-diploid cells and is generally considered to be a
marker for the presence of apoptotic cell death.
4. Discussion
The primary objective of this study was to iden-
tify the anti-proliferative properties of the parent
ligand, coumarin-dioxy-acetic acid (cdoaH2) and its
copper complex, copper-coumarin-dioxyacetic acetate-
phenathroline ([Cu(cdoa)(phen)2]). We also attempted, on cell cycle progression was determined in Hep-G2 cells, following
progression (panel B), with the appearance of a sub-G1 peak (panel
s.
to determine whether this complex could selectively
kill human neoplastic cells, leaving non-neoplastic cells
viable. In addition, we sought to elucidate the molecular
mechanism underlying the pharmacology of this com-
plex. In order to highlight the potential advantage of this
complex, comparative studies were carried out using one
of the best known and most widely used metal-based
anti-cancer drugs, cisplatin. Furthermore, this is the first
study of its kind to determine the potential application
of this complex as a novel anti-proliferative agent.
Initial anti-proliferative studies were carried out to
determine the IC50 value for the ligand and the complex,
along with the simple metal salt Cu(ClO4)2, phen and
cisplatin, using four human-derived model cell lines, two
derived from neoplatic origin and two of non-neoplastic
origin. It was intended that this approach would allow
us to determine whether the observed anti-proliferative
effect was due to the entire copper–coumarin–phen com-
plex, rather than the metal-free ligand, phen or the
simple aquated copper metal ion. Additionally, it was
hoped that that this might also provide a means by
which the potential cyto-selective nature of the complex
could be identified. We considered a compound to be
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yto-selective if the IC50 value obtained for the non-
eoplastic-derived cells was statistically greater from
hat obtained for cells of neoplastic origin. It was obliv-
ous that a compound which could act in this manner
ould offer significant advantage in the successful treat-
ent and management of cancer in man.
Initial anti-proliferative studies were carried out to
etermine the IC50 value of test agents, using all four
uman-derived model cell lines following 96 h exposure.
esults presented in Figs. 2 and 3 and Table 1, show
hat the complex had IC50 values significantly lower
han that recorded for the metal-free ligand, phen or the
ree metal salt. Furthermore, the complex displayed both
concentration- and time-dependent anti-proliferative
ffect. Additionally, the complex appeared to be the most
otent agent tested, as it had an IC50 value which was
pproximately 6 times more active than cisplatin, and in
oth Hep-G2 and A-498 cells. Also, the results obtained
uggest that Hep-G2 cells were significantly more sen-
itive than Chang, but this effect was not seen with
he non-neoplastic renal (HK-2) cells. Consequently, it
ould appear that like cisplatin, the complex is capable
f reducing the proliferative capacity of cells, but not in
cyto-selective manner.
In the initial part of the study we showed that the
omplex could kill hepatic and renal neoplastic cells
ollowing 96 h incubation. However, this did not pro-
ide information on the cytotoxicity associated with
his compound following relatively short exposure time
oints such as 4 and 24 h. Therefore, MTT-based via-
ility assays were conducted at these earlier time-points
nd the IC50 values again determined. The data obtained
Fig. 4) shows that even at these relatively short exposure
imes, the complex was capable of causing a potent anti-
roliferative effect, with IC50 values of 49 and 15M,
or 4 and 24 h, respectively. Therefore, where possi-
le these concentrations and time-points were used to
robe observed anti-proliferative response, along with
lucidating the molecular mechanism of action of the
omplex.
The morphology of treated cells was used to deter-
ine the extent and nature of cytological effects. Two
ifferent staining techniques were employed. Firstly,
ells were stined with methylene blue and eosin in order
o determine if gross morphological changes could be
bserved. The second stain used was DAPI. This stain
s specific for visualisation for nuclear morphology and
etection of DNA condensation. Results presented in
igs. 7 and 8 clearly show that the complex could induce
hanges which are consistent with the induction of both
poptotic and necrotic cell death. In addition, it would
ppear that the mode of cell death was dependent oneractions 168 (2007) 143–158 155
both drug concentration and incubation time, as it would
appear that higher doses and longer incubation times may
be required to switch from apoptosis to necrosis.
In an attempt to provide evidence for the involvement
of many of the biochemical processes which are central
to controlling the underlying mechanisms, it was decided
to study a number of the key features of cell death. There-
fore, additional studies were carried out using genomic
DNA isolated from cells treated with the complex. Cleav-
age of genomic DNA by endogenous endonucleases
during apoptosis is an irreversible event that commits
the cell to die [46]. The results presented in Fig. 9 show
that by 24 h, Hep-G2 cells treated with the complex had
activated the necessary endonucleases, such that endonu-
cleolytic cleavage of DNA at internucleosomal linker
sites had occurred. In addition, increasing complex con-
centration of complex appeared to cause band smearing,
suggesting the possible induction of necrotic cell death.
It is now widely accepted that activation of the caspase
cascade occurs upstream of DNA fragmentation [42,47].
This activation serves to induce the proteolytic cleavage
of a wide range of substrates. Caspase-3 is known to
cleave and inactivate the inhibitor of caspase-activated
DNAase, which in turn causes the release of active
endonucleases which translocate into the nucleus in
order to activate internucleosomal DNA fragmentation,
ultimately serving as a trigger for phagocytosis [42,48].
In addition, caspase-3 activation leads to increased cleav-
age of PARP, a known substrate of caspase-3 [48].
Proteolytic cleavage of native PARP (116 kDa) results
in separation of the N-terminal binding domain (24 kDa)
from its C-terminal catalytic domain (89 kDa) [49,50].
This is also an early critical event required for tumour
cells that have been exposed to DNA-damaging agents
and have committed to die by apoptosis. Therefore, we
decide to investigate the involvement of both caspase-
3 and -9 in mediating the mechanism of action of the
complex (Fig. 10). Data obtained demonstrates that the
complex could mediate the activity of both caspase-3
and -9, leading to PARP cleavage.
The ability of the complex to target DNA through an
inhibition of synthesis was demonstrated and presented
in Fig. 5. Additionally, we have shown (Fig. 6) that it was
non-intercalative, but that it was capable of decreasing
DNA synthesis (Fig. 5). Based on the findings presented
here, we were confident that the effect on DNA synthe-
sis was linked, not just to an anti-proliferative effect, but
also to the machinery associated with cell division, and
ultimately an ability to induce cell death. Consequently,
Hep-G2 cells were exposed to test agent (4, 8 and 16M)
for 24 h and the percentage of cells entering each phase of
the cell cycle was determined (Fig. 12). This finding sug-
ical In156 B. Thati et al. / Chemico-Biolog
gests that the complex caused a concentration-dependant
decrease in the % of cells entering G0/G1 and G2/M.
These data indicate that the complex was capable of
preventing cell cycle progression. It is now widely estab-
lished that progression is a tightly ordered and regulated
process involving multiple checkpoints. These check-
points respond to a variety of growth signals, alterations
in cell size and DNA integrity [51–53]. We postulate that
the complex may act on these checkpoints, preventing
further cell division and subsequently initiating death by
apoptosis and/or necrosis. However, this theory has not
yet been proven experimentally. It is worth noting that
the test concentrations used in this part of the study were
lower than those used before. These lower concentrations
were chosen as a higher concentration of 30M lead to
complete degradation of DNA, making it impossible to
determine effects on cell cycle. This finding suggests
that when cells were exposed to higher drug concen-
trations, they may undergo necrotic cell death, and by
a mechanism which was caspase-dependant (Fig. 9).
This theory may help explain the findings presented in
Fig. 8, using DAPI staining, where cells display charac-
teristics consistent with both apoptotic and necrotic cell
death. Examination of the flow cytometric histograms
(Fig. 11A) indicated the presence of a sub-G1 peak
which increased with increasing concentration (16M).
However, a very similar concentration (15M) did not
produce a statistically significant increase in caspase-9
activity and PARP cleavage (Figs. 10 and 11). Taken
together, this would suggest that cell death my occur via
either a caspase-independent or -dependent mechanism
with concurrent blockage of cell cycle events. Recently,
caspase-independent apoptosis has been observed in sev-
eral cell types [54,55]. Researchers have shown that
one of the proteins responsible for caspase-independent
chromatin condensation is apoptosis-inducing factor
(AIF) [56]. AIF is a 57 kDa flavoprotein which is con-
fined to the mitochondrial inter-membrane space of
healthy cells. However, upon exposure to lethal agents,
AIF translocates from the mitochondria to the nucleus,
via the cytosol. Although this protein may induce
caspase-independent peripheral chromatin condensation
and large-scale DNA fragmentation, the underlying
molecular signalling mechanism remains to be identi-
fied. Consequently, the possibility remains that that the
complex studied here may function through AIF.
In conclusion, the results from this study clearly indi-
cate that [Cu(cdoa)(phen) ], rather than the parent ligand2
[CdoaH2], phen, or the simple salt, could act as a potent
anti-proliferative agent. However, there is insufficient
evidence to suggest that it could function in a cyto-
selective manner. Additionally, we have shown that thisteractions 168 (2007) 143–158
complex can induce morphological and biochemical fea-
tures consistent with the induction of both apoptotic and
necrotic cell death. However, concentration of the com-
plex may be one of the main factors which causes a cell to
switch between the two modes of death. Additional stud-
ies are currently underway by which both the number of
apoptotic cells can be accurately quantified, and the role
of regulatory proteins associated with cell division and
death can be determined more fully. Furthermore, we
intend to elucidate the inter-relationship between these
regulatory proteins and those associated with signalling
proteins, such as the mitogen-activated protein kinases
which are known to control cellular proliferation, death
and differentiation [57]. It is hoped that results from these
studies will allow identification of additional molecular
targets, which may further assist in the elucidation of the
mechanism of action of this complex.
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